Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6310363 | 0.89 | PDE4B (0.59) | DPP4PDE4BMEN1KMT2ACNR1 | |
| SCHEMBL16780715 | 0.86 | PDE4B (0.48) | PDE4BMEN1KMT2ACNR1RORC | |
| SCHEMBL31450144 | 0.86 | PDE4B (0.48) | PDE4BMEN1KMT2ACNR1RORC | |
| SCHEMBL16780718 | 0.86 | PDE4B (0.48) | PDE4BMEN1KMT2ACNR1RORC | |
| SCHEMBL16780714 | 0.86 | PDE4B (0.48) | PDE4BMEN1KMT2ACNR1RORC | |
| SCHEMBL23216432 | 0.85 | PDE4B (0.48) | DPP4PDE4BCNR1MC4RRORC | |
| SCHEMBL24946334 | 0.85 | PDE4B (0.48) | DPP4PDE4BCNR1MC4RRORC | |
| SCHEMBL29768413 | 0.85 | PDE4B (0.48) | DPP4PDE4BCNR1MC4RRORC | |
| SCHEMBL13858719 | 0.84 | PDE4B (0.57) | PDE4BMC4RRORCTACR1STS | |
| SCHEMBL16780015 | 0.84 | PDE4B (0.57) | PDE4BMC4RRORCTACR1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192286-A1 | Ligands of melanocortin receptors and compositions and methods related thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192286-A1 | Ligands of melanocortin receptors and compositions and methods related thereto | MC3R, MC1R, MC5R | DPP4 3446/4885PDE4B 892/4885MEN1 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.